Beijing China said on Thursday that it has conditionally approved the Kovid-19 vaccine developed by China’s National Pharmaceutical Group (Cyanopharm). The South China Morning Post quoted Chinese officials as saying that the vaccine would be made available free of cost under the National Immunization Program.
China previously authorized emergency use of vaccines for high-risk groups. “Last night, we approved the vaccine made by the China National Pharmaceutical Group’s Beijing Institute of Biological Products according to the law,” said Chen Shaifi, deputy head of the National Medical Products Administration.
According to the interim results of the Phase III clinical trial, the vaccine has shown 79.34 percent efficacy against Kovid-19.
Reportedly, antibodies remained in all people taking the vaccine after the 2-dose inoculation process, and the seroconversion rate of neutralizing antibodies reached 99.52 percent.
The vaccine is developed by Sinopharm, a subsidiary of the Beijing Institute of Biological Products.
Warning: Trying to access array offset on value of type bool in /home/todaynewsindia/domains/en.todaynewsindia.com/public_html/wp-content/themes/goodnews5/framework/e3lanat/ads-system.php on line 185
Leave a Reply